USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novo Nordisk A/S

USPTO PatentsView assignee record - 503 granted patents across 63 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Novo ranks #893 of 49,997 tracked US assignees by granted-patent volume, with 503 patents across 63 technology areas.

#893
of 49,997 US assignees by volume
Top 3%
by Innovation Score (61.4/100)
14.3
avg claims per patent
-28%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R893 · Foreign Corporation #893 · 503 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MID 503 grants
  • TOP-DECILE #893/49,997
  • PHOTO-FINISH KLA
  • CPC-WIDE A61M · 63 areas
  • INNOV-STRONG 61.4/100
  • CLAIMS-RICH 14.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -28% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: KLA Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Novo

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Novo's Innovation Score is 61.4/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Novo's grant cadence moved

Between 2020–2024, Novo Nordisk A/S received 201 grants versus 278 in 2015–2019 (-28% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2015 at 66 grants and bottomed in 2024 at 32. Lead class A61M accounts for 45.3% of the portfolio across 63 subclasses. Volume neighbours: Sumitomo Metal Mining Co., Ltd. (#889) and Atlassian PTY Ltd. (#897).

Novo's three-year grant acceleration

From 2019–2021 to 2022–2024, Novo Nordisk A/S moved from 132 to 125 grants (0.95x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,329. See the growth leaderboard.

Who files at Novo's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Novo holds 503 patents at rank #893, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Novo

By rank, the assignees closest to #893 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Novo's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novo, neither rank-band nor same-CPC leaders (those blocks stay above).

Novo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

61 Top 3% higher than 97% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

203040506070 20152016201720182019202020212022202320242025 24
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Novo Nordisk A/S patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 66 13.1%
2016 53 10.5%
2017 53 10.5%
2018 50 9.9%
2019 56 11.1%
2020 34 6.8%
2021 42 8.3%
2022 57 11.3%
2023 36 7.2%
2024 32 6.4%
2025partial year 24 4.8%

Which technologies does Novo Nordisk A/S patent most?

Top 15 of 63 technology areas

Where it ranks

Overall rank by patents

#893

of 49,997 tracked assignees

Innovation Score

61.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Novo Nordisk A/S's patent record in context - here's where to go next.

  • Novo Nordisk A/S's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 45.3% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #893 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Novo Nordisk A/S against Sumitomo Metal Mining Co., Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 61.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.